Moleculin Biotech Stock Coverage and Analysis at StockNews
Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
- Latest
- Trending
Moleculin Biotech's stock has been given a "sell" rating by a firm, with a 1-year low of $4.34 and a ...
Atticus Wealth Management LLC buys stake in Moleculin Biotech as the firm sets a “sell” rating on the stock; MBRX ...
Losses are expected to increase by 32% to CN¥3.15 per share for Sichuan Kelun-Biotech Biopharmaceutical. This is a significant change ...
NextCure, Inc. (NXTC) is a biopharmaceutical company focused on novel immunomedicines. Strong financials, positive outlook, and promising pipeline.
Ventyx Biosciences, Inc. (VTYX) is a high-risk investment with negative net income and high debt ratio, but analysts recommend buying ...
Adial Pharmaceuticals, Inc. - A biopharmaceutical company focusing on addiction therapeutics. Stock faced challenges this year, with price drops. Leadership ...
Discover the financial report of Theratechnologies Inc., a biopharmaceutical company specializing in healthcare therapies. Learn about their market cap, leadership ...
Experience Ligand Pharmaceuticals Incorporated's financial report and stock price prediction in the healthcare sector. Discover their strategic growth trajectory.
Digital bioprocessing technologies will help drug makers improve product quality, reduce manufacturing costs, and fully embrace quality-by-design (QbD), according to ...
Nocion Therapeutics raises $62M in Series B funding, bringing total funding to $122M. The biopharmaceutical company is developing small molecule ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.